Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013668992> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2013668992 endingPage "A306" @default.
- W2013668992 startingPage "A306" @default.
- W2013668992 abstract "Evaluate direct costs for the treatment of patient with active juvenile rheumatoid arthritis (JRA) in the inefficiency of conventional therapy. Direct costs applied to patient, health care and society in process of medical care provision were evaluated. In the study direct costs included cost of biologics for the treatment of active JRA, therapy cost of the most common side effects caused by biologics use, cost of inpatient care and cost of out-patient diagnostic and treatment of JRA patients. Therapy cost with Etanercept and Abatacept was evaluated on the first stage including spending on one patient treatment with active JRA with body weight 15 till 65 kg. during one year after three months of inefficient conventional therapy. Biologics doses and dosing regimen were defined on the basis of application sheet. Calculated annual therapy cost for Etanercept varied from 11,752 EUR to 23,503 EUR depending on body weight and for Abatacept from 8,879 EUR to 26,638 EUR respectively. During cost analysis authors considered only very often (>1/10) and often (>1/100, < 1/10) occurred side effects. Thus, cost of side effects treatment caused by Etanercept use resulted in 44 EUR and for Abatacept – 69 EUR. Next stage of cost analysis was evaluation of therapy cost for patients with JRA according standard of inpatient treatment è standard of out-patient treatment. Cost of 30 days of inpatient care and 14 months of out-patient care was considered during cost analysis for the treatment of patients with JRA. Cost of inpatient and out-patient care for patient with JRA excluding biologics cost amounted to 33585 EUR. Finally total direct costs for the treatment of patient with JRA during one year with body weight from 15 till 65 kilogram varied from 45,380 EUR to 57,132 EUR for Etanercept and from 42,534 EUR to 60,292 EUR for Abatacept respectively." @default.
- W2013668992 created "2016-06-24" @default.
- W2013668992 creator A5012651894 @default.
- W2013668992 creator A5020267982 @default.
- W2013668992 creator A5044907261 @default.
- W2013668992 date "2011-11-01" @default.
- W2013668992 modified "2023-09-30" @default.
- W2013668992 title "PMS25 Evaluation of Direct Costs for the Treatment of Active Juvenile Rheumatoid Arthritis Using Biologics" @default.
- W2013668992 doi "https://doi.org/10.1016/j.jval.2011.08.411" @default.
- W2013668992 hasPublicationYear "2011" @default.
- W2013668992 type Work @default.
- W2013668992 sameAs 2013668992 @default.
- W2013668992 citedByCount "1" @default.
- W2013668992 countsByYear W20136689922016 @default.
- W2013668992 crossrefType "journal-article" @default.
- W2013668992 hasAuthorship W2013668992A5012651894 @default.
- W2013668992 hasAuthorship W2013668992A5020267982 @default.
- W2013668992 hasAuthorship W2013668992A5044907261 @default.
- W2013668992 hasBestOaLocation W20136689921 @default.
- W2013668992 hasConcept C112930515 @default.
- W2013668992 hasConcept C121955636 @default.
- W2013668992 hasConcept C126322002 @default.
- W2013668992 hasConcept C141071460 @default.
- W2013668992 hasConcept C144133560 @default.
- W2013668992 hasConcept C2777226972 @default.
- W2013668992 hasConcept C2777575956 @default.
- W2013668992 hasConcept C2779338263 @default.
- W2013668992 hasConcept C2779605438 @default.
- W2013668992 hasConcept C2780653079 @default.
- W2013668992 hasConcept C2781413609 @default.
- W2013668992 hasConcept C3019080777 @default.
- W2013668992 hasConcept C6964187 @default.
- W2013668992 hasConcept C71924100 @default.
- W2013668992 hasConceptScore W2013668992C112930515 @default.
- W2013668992 hasConceptScore W2013668992C121955636 @default.
- W2013668992 hasConceptScore W2013668992C126322002 @default.
- W2013668992 hasConceptScore W2013668992C141071460 @default.
- W2013668992 hasConceptScore W2013668992C144133560 @default.
- W2013668992 hasConceptScore W2013668992C2777226972 @default.
- W2013668992 hasConceptScore W2013668992C2777575956 @default.
- W2013668992 hasConceptScore W2013668992C2779338263 @default.
- W2013668992 hasConceptScore W2013668992C2779605438 @default.
- W2013668992 hasConceptScore W2013668992C2780653079 @default.
- W2013668992 hasConceptScore W2013668992C2781413609 @default.
- W2013668992 hasConceptScore W2013668992C3019080777 @default.
- W2013668992 hasConceptScore W2013668992C6964187 @default.
- W2013668992 hasConceptScore W2013668992C71924100 @default.
- W2013668992 hasIssue "7" @default.
- W2013668992 hasLocation W20136689921 @default.
- W2013668992 hasOpenAccess W2013668992 @default.
- W2013668992 hasPrimaryLocation W20136689921 @default.
- W2013668992 hasRelatedWork W1964728291 @default.
- W2013668992 hasRelatedWork W1979392798 @default.
- W2013668992 hasRelatedWork W2062697678 @default.
- W2013668992 hasRelatedWork W2089251437 @default.
- W2013668992 hasRelatedWork W2112121938 @default.
- W2013668992 hasRelatedWork W2162936925 @default.
- W2013668992 hasRelatedWork W2238463541 @default.
- W2013668992 hasRelatedWork W2328891906 @default.
- W2013668992 hasRelatedWork W2346701512 @default.
- W2013668992 hasRelatedWork W94518001 @default.
- W2013668992 hasVolume "14" @default.
- W2013668992 isParatext "false" @default.
- W2013668992 isRetracted "false" @default.
- W2013668992 magId "2013668992" @default.
- W2013668992 workType "article" @default.